Nestlé Invests $200 Million More in Peanut Drug

Feb. 7, 2020
Nestlé has doubled down on its bet on a new therapy for peanut allergies.

Nestlé has doubled down on its bet on a new therapy for peanut allergies.

Palforzia, from Aimmune Therapeutics Inc., treats peanut allergies by reducing the trauma suffered by allergic individuals upon exposure to peanuts. A powder made from peanuts, Palforzia is administered in escalating doses over an 11-month period. It does not cure peanut allergies, and sufferers must continue to avoid peanuts, but it mitigates the potentially fatal consequences of peanut exposure.

The FDA approved Palforzia on Jan. 31, and Aimmune announced on Feb. 5 that Nestlé had invested another $200 million in the drug. Nestlé had previously made investments totaling $273 million.

Nestlé’s involvement is seen as a way to increase revenue from its Health Science division and pivot away from food, where sales have stagnated.

Sponsored Recommendations

Troubleshoot: Grittiness in gluten free cookies

Learn how to adjust gluten free cookie recipes for a softer texture.

Clabber Girl: Rising Success

Uncover how Clabber Girl Corporation achieved a remarkable 7% growth and improved manufacturing efficiency by seamlessly integrating Vicinity's batch manufacturing solution with...

Intelligent Blends: Taking Technology to the Next Level

Find out how our friends at Intelligent Blends use VicinityFood and Microsoft Dynamics GP to produce the best coffee around.

Key ingredient: Mother Murphy's Laboratories

Flavorings manufacturer Mother Murphy’s Laboratories integrates front office with production facility — improving operations from initial order to final invoice.